The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
it did get approved in Europe for some time for that indication o for reize women with low desire and it was used off label in other postmenopausal women — it went off the market for reasons other than efficacy or safety and it's no longer available in Europe as a 300
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and the main thing in small percentage of women was what's called heroism so it was a little hair growth like on the face along the nipple — and the acne was relatively mild and women did well right and they liked it and — it was brought to the FDA at that time and the issue wasn't efficacy it was lack of long-term safety data